Case Report of CCDC149–ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma
- 1 December 2022
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 32 (12), 1580-1585
- https://doi.org/10.1089/thy.2022.0389
Abstract
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, usually with an indolent course. ALK fusions are rare in PTC but may give rise to a more aggressive behavior. We report a novel ALK fusion, CCDC149-ALK, not previously described in PTC, detected by next generation sequencing (NGS) in a 30 year-old woman with progressive, widely metastatic radioiodine-refractory (RAIR) disease to lung, muscle, and brain. The patient was started on alectinib, a second-generation ALK inhibitor. Within 8 weeks, her palpable disease had completely regressed, and the serum thyroglobulin decreased dramatically. Restaging imaging demonstrated an objective partial response. Our case highlights the role of ALK fusions in thyroid cancer and highlights its clinical significance in PTC. We recommend deep mutational sequencing in BRAFV600E-negative, RAIR PTC to identify targetable genetic alterations, including gene fusions, that may result in dramatic therapeutic benefits.Keywords
This publication has 24 references indexed in Scilit:
- The Transcriptional Roles of ALK Fusion Proteins in TumorigenesisCancers, 2019
- Gene Fusions in Thyroid CancerThyroid®, 2018
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyThe Lancet, 2017
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung CancerCancer Discovery, 2016
- Biologic and Clinical Perspectives on Thyroid CancerThe New England Journal of Medicine, 2016
- Dramatic Survival Benefit with Nivolumab in MelanomaCancer Discovery, 2016
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersJCI Insight, 2016
- A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid CarcinomaThe American Journal of Surgical Pathology, 2015
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007